Bull
$210.76
Scenario price
$144.440
+0.910 (+0.63%)At close
Align Technology, Inc. is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad computer-aided design and computer-aided manufacturing (CAD/CAM) software for digital orthodontics and restorative dentistry. The Company provides Align Digital Platform. Its segments include Clear Aligner, and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment consists of comprehensive products, non-comprehensive products and non-case products. Its comprehensive products include Invisalign Comprehensive and Invisalign First. The Company's non-case products include retention products, Invisalign training and adjusting tools. It offers up to four sets of custom clear aligners called Vivera retainers. The Systems and Services segment consists of its iTero intraoral scanning systems. Its services include subscription software, disposables, rentals, leases and pay per scan services.
Align Technology Inc is currently a hold. The stock is trading at $142.71, which is significantly below the average analyst price target of $189, indicating potential upside. However, the stock has a relatively low RSI of 45.75, suggesting it may not be oversold, and recent downgrades from analysts reflect concerns about weakening demand and economic conditions. The forward P/E ratio of 11.67 is attractive compared to its historical performance, but the stock has dropped 8.54% year-to-date, indicating ongoing challenges. The main risk is the recent analyst downgrade citing a sharp deceleration in demand indicators, which could impact future earnings.
Stifel
$175
2026-10-09
Stifel
2026-10-09
Price Target
$175
Evercore ISI
$155
2026-10-05
Evercore ISI
2026-10-05
Price Target
$155
UBS
$189
2026-07-23
UBS
2026-07-23
Price Target
$189
BMO Capital
$209
2026-07-08
BMO Capital
2026-07-08
Price Target
$209
Leerink
$230
2026-06-30
Leerink
2026-06-30
Price Target
$230
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Align Technology to Report Q3 2026 Financial Results

Align Technology Stock Performance Analysis

Weak US Retail Sales Impact Markets

Align Technology Wins Patent Infringement Case Against Angelalign

Align Wins Patent Infringement Case in China, Awarded RMB 10 Million
Align Technology, Inc. is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad computer-aided design and computer-aided manufacturing (CAD/CAM) software for digital orthodontics and restorative dentistry. The Company provides Align Digital Platform. Its segments include Clear Aligner, and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment consists of comprehensive products, non-comprehensive products and non-case products. Its comprehensive products include Invisalign Comprehensive and Invisalign First. The Company's non-case products include retention products, Invisalign training and adjusting tools. It offers up to four sets of custom clear aligners called Vivera retainers. The Systems and Services segment consists of its iTero intraoral scanning systems. Its services include subscription software, disposables, rentals, leases and pay per scan services. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).
Align Technology Inc is currently a hold. The stock is trading at $142.71, which is significantly below the average analyst price target of $189, indicating potential upside. However, the stock has a relatively low RSI of 45.75, suggesting it may not be oversold, and recent downgrades from analysts reflect concerns about weakening demand and economic conditions. The forward P/E ratio of 11.67 is attractive compared to its historical performance, but the stock has dropped 8.54% year-to-date, indicating ongoing challenges. The main risk is the recent analyst downgrade citing a sharp deceleration in demand indicators, which could impact future earnings.
11 analysts cover ALGN: 11 rate it Buy, 0 Hold and 0 Sell. The average price target is 198.70.
No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.